Mexidol (Emoxypin, aka Emoxipine, Epigid)

Instructions for Mexidol

Composition Mexidol:

Active ingredients: ethylmethylhydroxypyridine succinate 125 mg.

pharmachologic effect Mexidol:

Antioxidant agent.

Pharmacodynamics Mexidol:

Improves metabolism and blood supply to the brain. Improves microcirculation and rheological properties of blood, reduces platelet aggregation

pharmachologic effect Mexidol:

The mechanism of action of Mexidol is due to its antioxidant, antihypoxant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the ratio of lipid-protein, reduces the viscosity of the membrane, increases its fluidity. Mexidol modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, contributes to the preservation of the structural and functional organization biomembrmes, and unset.

increases the dopamine content in the brain. It causes increased compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

The drug improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structure of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins.

The antistress effect is manifested in the normalization of post-stress behavior, somatic vegetative disturbances, restoration of sleep-wake cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various brain structures.

Mexidol has a pronounced anti-toxic effect in withdrawal symptoms. It eliminates the neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disturbances, autonomic functions, and is also capable of alleviating cognitive impairments caused by prolonged use of ethanol and its withdrawal. Under the influence of, the effect of tranquilizing, neuroleptic, anti-depressive, hypnotic and anticonvulsant drugs is enhanced, which makes it possible to reduce their doses and reduce side effects. Mexidol® improves the functional state of the ischemic myocardium. Under conditions of coronary insufficiency, it increases the collateral blood supply to the ischemic myocardium, contributes to preserving the integrity of cardiocytes and maintaining their functional activity.

Pharmacokinetics Mexidol:

Suction

With the introduction of Mexidol in doses of 400-500 mg Cmax in plasma is 3.5-4.0 µg / ml and is achieved within 0.45-0.5 h.

Distribution

After i / m administration, the drug is determined in the blood plasma for 4 hours. The average retention time of the drug in the body is 0.7-1.3 h.

Removal

Excreted from the body with urine mainly in glucurono-conjugated form and in small quantities in unchanged form.

Indications Mexidol:

the consequences of acute cerebral circulatory disorders, including after transient ischemic attacks, in the subcompensation phase as prophylactic courses
mild traumatic brain injury, the effects of traumatic brain injury
encephalopathies of various origins (dyscirculatory, dysmetabolic, post-traumatic, mixed)
vegetative dystonia syndrome
mild cognitive impairment of atherosclerotic genesis
anxiety disorders in neurotic and neurosis-like conditions
conditions after acute intoxication with antipsychotics
asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads
exposure to extreme (stress) factors
ischemic heart disease as part of complex therapy
relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-abstinent disorders
Use during pregnancy and lactation
No strictly controlled clinical studies of the safety of using Mexidol® during pregnancy and lactation have been conducted.

Contraindications Mexidol:

acute liver failure

acute renal failure

hypersensitivity to the drug.
Due to the lack of knowledge of the action of the drug:

childhood;
pregnancy;
lactation period (breastfeeding).

Side effects Mexidol:

When using the drug are possible:

On the part of the digestive system: the appearance of individual adverse reactions may be dyspeptic or dyspeptic.

Other: possible allergic reactions.

Interaction

When combined, Mexidol® enhances the effect of benzodiazepine derivatives, antidepressants, anxiolytics, anti-Parkinsonian and anticonvulsant drugs.

Mexidol reduces the toxic effect of ethanol.

Overdose Mexidol:

Overdose may cause drowsiness.

Special instructions

Precautions when taking the drug

Mexidol can be combined with all drugs used to treat somatic diseases.

Use in Pediatrics

Mexidol is not prescribed to children due to insufficient knowledge of the drug's action.

Impact on the ability to drive vehicles and other mechanisms that require high concentration of attention

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor speed.

Alcohol Interaction

Mexidol reduces the toxic effect of ethanol.

How to take Mexidol

Method of administration and dosage regimen, depending on the symptoms

Inside 125-250 mg 3 times / day; the maximum daily dose is 800 mg (6 tab.). The duration of treatment is 2-6 weeks; for stopping alcohol withdrawal - 5-7 days. Treatment is stopped gradually, reducing the dose within 2-3 days.

Initial dose - 125-250 mg (1-2 tab.) 1-2 times / day with a gradual increase to obtain a therapeutic effect; the maximum daily dose is 800 mg (6 tab.).

The duration of therapy in patients with coronary artery disease is at least 1.5-2 months. Repeated courses (according to the recommendation of the doctor) are preferably carried out in the spring and autumn periods.